Published in Mol Cell Proteomics on July 08, 2011
Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener (2016) 1.41
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J Exp Med (2013) 1.27
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2012) 1.07
Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2013) 0.99
Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One (2013) 0.88
Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord (2013) 0.85
Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease. JAMA Neurol (2015) 0.81
Ageing, neurodegeneration and brain rejuvenation. Nature (2016) 0.80
Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses. Mol Genet Metab (2014) 0.79
How predictive of dementia are peripheral inflammatory markers in the elderly? Neurodegener Dis Manag (2012) 0.78
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol (2015) 0.76
Discovery of Novel Biomarkers for Alzheimer's Disease from Blood. Dis Markers (2016) 0.75
Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients. Alzheimers Res Ther (2016) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res (1990) 14.82
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics (2006) 5.04
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol (2007) 4.13
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol (2010) 2.42
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
The impact of cellular networks on disease comorbidity. Mol Syst Biol (2009) 2.23
Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol (2010) 2.17
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain (2009) 1.84
Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol (2005) 1.61
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One (2009) 1.32
Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol (2010) 1.29
Nuanced roles of cytokines in three major human brain disorders. J Clin Invest (2008) 1.28
G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J Exp Med (2007) 1.24
Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci (2009) 1.24
Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics (2003) 1.12
A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis (2011) 1.10
Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem (2004) 1.04
A novel blood test for the early detection of Alzheimer's disease. J Alzheimers Dis (2011) 1.04
Fatty acid-binding proteins of nervous tissue. J Mol Neurosci (2001) 1.01
Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol (2007) 0.95
CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis (2010) 0.93
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest (2008) 4.09
Statins and the risk of cancer after heart transplantation. Circulation (2012) 4.06
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Limit Distribution Theory for Maximum Likelihood Estimation of a Log-Concave Density. Ann Stat (2009) 3.97
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 3.09
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain (2007) 2.96
A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry (2006) 2.85
A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry (2013) 2.84
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci (2009) 2.82
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Independent predictors of cognitive decline in healthy elderly persons. Arch Neurol (2002) 2.70
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry (2003) 2.59
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol (2002) 2.58
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc (2010) 2.34
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol (2004) 2.29
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Diagnostic evaluation of elderly patients with mild memory problems. Ann Intern Med (2003) 2.15
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc (2008) 2.13
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci (2004) 2.07
Trainee satisfaction in surgery residency programs: modern management tools ensure trainee motivation and success. Surgery (2011) 2.04
Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron (2003) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Unobtrusive assessment of activity patterns associated with mild cognitive impairment. Alzheimers Dement (2008) 1.95
Uric acid as a CNS antioxidant. J Alzheimers Dis (2010) 1.93
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry (2007) 1.91
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement (2008) 1.90
Is there a role for tamsulosin in the treatment of distal ureteral stones of 7 mm or less? Results of a randomised, double-blind, placebo-controlled trial. Eur Urol (2009) 1.87
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol (2002) 1.79
Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics (2007) 1.78
Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest (2007) 1.78
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement (2013) 1.77
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry (2013) 1.74